Today's Daily Dose brings you news about FDA approval of Amphastar's generic Bloxiverz; Arbutus' positive Cohort 4 results from phase II study of ARB-1467 in chronic HBV patients; the upcoming catalyst of Catalyst Biosciences; Genocea's decision to cease development of genital herpes drug candidate GEN-003 and Intellipharmaceutics' Complete response Letter for investigational opioid painkiller.
from RTT - Biotech http://ift.tt/2jZ8VoN
via IFTTT
No comments:
Post a Comment